Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Takeda CEO Earns 1.72 Billion Yen in FY2022, Down 135 Million Yen
June 29, 2023
- Keytruda Label Updated to Add Hodgkin Lymphoma Data
June 28, 2023
- UN-Backed Agency, 7 Firms Ink Deals for Generic Supply of Shionogi’s COVID Pill to LMICs
June 28, 2023
- Taiho, Kyushu University in Research Tie-Up on Covalent Reactive Groups
June 28, 2023
- Meiji Seika Pharma Files GVHD Drug Belumosudil in Japan
June 28, 2023
- UCB Japan Seeks Lennox-Gastaut Syndrome Indication for Fintepla
June 28, 2023
- Chugai to Form Corporate VC in Boston to Drive Innovation
June 28, 2023
- UBE, IPSC Startup Grab US Orphan Tag for IPF Therapy
June 28, 2023
- Rexulti Makes Mark in Japan PIII Study for Alzheimer’s Agitation: Otsuka
June 28, 2023
- Merck Biopharma, Pfizer Japan to End Bavencio Copromotion
June 28, 2023
- Amgen Japan to Cut 30 Jobs in Evenity Sales Unit as It Rejigs Organization
June 27, 2023
- Japan Approves Novartis’ Gene Therapy Luxturna for Rare Eye Disease
June 27, 2023
- Lonsurf-Bevacizumab Combo Nabs EU Panel Nod for Colorectal Cancer
June 27, 2023
- Shionogi Snaps Up Qpex to Boost Antimicrobial Pipeline
June 27, 2023
- Zenyaku Kogyo Bags Japan Rights to Singapore Firm’s Eczema Med
June 26, 2023
- Veritas, Takeda Link Up for mRNA-Targeted Drug Discovery against Genetic Disorders
June 26, 2023
- Japan Pharma Market Projected to Grow 0.5-1.5% through FY2027: IQVIA
June 26, 2023
- Nobelpharma Grants Authorized Generic Rights to Japanese Firm
June 26, 2023
- Shionogi CEO Hauls In 292 Million Yen after Record Year
June 26, 2023
- Kris Sisneros Takes Helm at LEO Pharma Japan
June 23, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…